Single-center, Open Trail of Phase 1 of M2ES With TC Regimen in Advanced NSCLC
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Adverse events incidence,including severe adverse events incidence
one year
Yes
Kai LI
Principal Investigator
Tianjin Medical University Cancer Institude and Hospital
China: Food and Drug Administration
TMU-CIH-CTI-001
NCT01099124
December 2009
September 2011
Name | Location |
---|